Crizanlizumab 5.0 Mg/Kg Increased the Time to First on-Treatment Sickle Cell Pain Crisis: A Subgroup Analysis of the Phase II Sustain Study
- Resource Type
- Abstract
- Source
- In
Blood 8 December 2017 130 Supplement 1:613-613 - Subject
- Language
- ISSN
- 0006-4971